UK Wegovy Pill Nod Highlights MHRA Autonomy Post-Brexit While Exposing Gaps in Long-Term Cost Modelling

The Medicines and Healthcare products Regulatory Agency approval of Novo Nordisk’s oral semaglutide formulation marks a regulatory milestone distinct from the injectable pathway cleared in 2021. Primary MHRA documentation emphasises bioequivalence data rather than new outcome trials, leaving open questions on real-world adherence versus the STEP programme results cited by the company. This decision aligns with broader UK policy shifts treating obesity as a chronic condition eligible for pharmacological intervention, yet it bypasses immediate integration with NICE’s ongoing multiple-technology appraisal that still weights injection costs. Secondary sources including the European Medicines Agency’s parallel review timeline reveal the UK acting independently, a direct consequence of post-Brexit divergence that has accelerated certain approvals but created divergence in post-marketing surveillance expectations. Supply-chain vulnerabilities for the active pharmaceutical ingredient, concentrated in Danish and US facilities, receive no mention in the Bloomberg coverage despite documented API shortages affecting other GLP-1 products in 2024–2025. Equity implications surface when contrasting NHS reimbursement criteria with private-market access, where daily oral dosing may favour higher-income patients able to avoid cold-chain storage. The original reporting understates these frictions between rapid market entry and fiscal sustainability within the National Health Service.